Charles River Laboratories Retained Earnings (Accumulated Deficit) 2010-2025 | CRL

Charles River Laboratories retained earnings (accumulated deficit) for the quarter ending March 31, 2025 were $1.838B, a 6.24% decline year-over-year.

  • Charles River Laboratories retained earnings (accumulated deficit) for 2024 were $1.812B, a 3.98% decline from 2023.
  • Charles River Laboratories retained earnings (accumulated deficit) for 2023 were $1.887B, a 31.71% increase from 2022.
  • Charles River Laboratories retained earnings (accumulated deficit) for 2022 were $1.433B, a 46.1% increase from 2021.

Charles River Laboratories Retained Earnings (Accumulated Deficit) 2010-2025 | CRL

  • Charles River Laboratories retained earnings (accumulated deficit) for 2024 were $1.812B, a 3.98% decline from 2023.
  • Charles River Laboratories retained earnings (accumulated deficit) for 2023 were $1.887B, a 31.71% increase from 2022.
  • Charles River Laboratories retained earnings (accumulated deficit) for 2022 were $1.433B, a 46.1% increase from 2021.